- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
40
40 companies
Axsome Therapeutics
Market Cap: US$8.0b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$156.92
7D
-0.8%
1Y
21.5%
Travere Therapeutics
Market Cap: US$2.5b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$26.84
7D
-4.2%
1Y
26.1%
Madrigal Pharmaceuticals
Market Cap: US$10.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$447.72
7D
1.6%
1Y
29.2%
Zevra Therapeutics
Market Cap: US$541.9m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$9.42
7D
-4.6%
1Y
14.7%
Syndax Pharmaceuticals
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$24.09
7D
0.2%
1Y
75.5%
Insmed
Market Cap: US$29.3b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$143.98
7D
-0.4%
1Y
81.4%
Marker Therapeutics
Market Cap: US$22.3m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
MRKR
US$1.34
7D
-5.0%
1Y
4.7%
Ardelyx
Market Cap: US$1.3b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.31
7D
-9.1%
1Y
1.1%
Rhythm Pharmaceuticals
Market Cap: US$6.0b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$87.45
7D
-3.4%
1Y
62.8%
ARS Pharmaceuticals
Market Cap: US$811.3m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.17
7D
-6.1%
1Y
-36.6%
Aldeyra Therapeutics
Market Cap: US$108.9m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$2.23
7D
-47.3%
1Y
-66.3%
Corcept Therapeutics
Market Cap: US$3.7b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$33.63
7D
4.5%
1Y
-43.5%
Pelthos Therapeutics
Market Cap: US$69.6m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$22.00
7D
-8.3%
1Y
48.6%
Capricor Therapeutics
Market Cap: US$1.7b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$30.10
7D
-1.5%
1Y
126.7%
AC Immune
Market Cap: US$282.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.85
7D
-8.9%
1Y
34.4%
Viridian Therapeutics
Market Cap: US$2.8b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$27.62
7D
-4.0%
1Y
78.7%
Kiniksa Pharmaceuticals International
Market Cap: US$3.5b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$46.04
7D
-1.0%
1Y
96.7%
CG Oncology
Market Cap: US$5.5b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$64.96
7D
-1.4%
1Y
127.7%
Arcutis Biotherapeutics
Market Cap: US$2.8b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$22.29
7D
-2.1%
1Y
28.9%
CollPlant Biotechnologies
Market Cap: US$8.9m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$0.61
7D
-0.5%
1Y
-80.4%
SIGA Technologies
Market Cap: US$353.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.94
7D
-9.5%
1Y
-17.4%
Invivyd
Market Cap: US$390.0m
Engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
IVVD
US$1.38
7D
-17.4%
1Y
90.6%
Belite Bio
Market Cap: US$6.1b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$151.14
7D
-8.6%
1Y
125.8%
Verrica Pharmaceuticals
Market Cap: US$93.6m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$4.85
7D
-21.4%
1Y
-7.1%
BeOne Medicines
Market Cap: US$30.5b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$274.73
7D
-5.2%
1Y
8.5%
Praxis Precision Medicines
Market Cap: US$8.3b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$294.11
7D
-3.6%
1Y
679.9%
Krystal Biotech
Market Cap: US$7.4b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$250.08
7D
-0.03%
1Y
28.6%
Mirum Pharmaceuticals
Market Cap: US$5.3b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$88.51
7D
-4.5%
1Y
88.2%
Gyre Therapeutics
Market Cap: US$613.6m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$6.72
7D
-10.4%
1Y
-27.0%
Amicus Therapeutics
Market Cap: US$4.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.43
7D
0.4%
1Y
66.1%
Journey Medical
Market Cap: US$220.5m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$6.90
7D
-7.4%
1Y
5.5%
Benitec Biopharma
Market Cap: US$376.1m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$11.19
7D
-6.8%
1Y
-22.0%
Prelude Therapeutics
Market Cap: US$246.8m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$3.16
7D
-6.0%
1Y
338.9%
Arcellx
Market Cap: US$6.7b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$114.60
7D
0.08%
1Y
58.1%
Fortress Biotech
Market Cap: US$92.8m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.98
7D
-3.6%
1Y
73.3%
Protagonist Therapeutics
Market Cap: US$6.3b
Operates as a discovery and development company in the United States.
PTGX
US$98.87
7D
2.2%
1Y
88.2%